Aurobindo Expects To Be In Top Three For Immunology Biosimilar – Is It Xolair?
Pneumococcal Vaccine Filing In H2
Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar, potentially a version of Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23.
You may also be interested in...
After earlier this year revealing that it had dropped a collaboration with BiosanaPharma on a biosimilar omalizumab rival to Xolair, Alvotech has now announced a fresh licensing deal for development and commercialization of a version from Kashiv BioSciences.
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.
With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.